Hairloss Study Abstract: Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition.
Title
Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various
commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition.
Author
Rhodes L; Primka RL; Berman C; Vergult G; Gabriel M; Pierre-Malice M; Gibelin B
Address
Department of Biochemistry, Merck Research Laboratories, Rahway, New Jersey 07065.
Source
Prostate, 1993, 22:1, 43-51
Abstract
Human prostate was used as a source of 5 alpha reductase. Compounds were incubated with
an enzyme preparation and [3H]testosterone. [3H]-dihydrotestosterone production was
measured to calculate 5 alpha reductase activity. IC50 values (ng/ml) were finasteride =
1; Permixon = 5,600; Talso = 7,000; Strogen Forte = 31,000; Prostagutt = 40,000; and
Tadenan = 63,000. Bazoton and Harzol had no activity at concentrations up to 500,000
ng/ml. In castrate rats stimulated with testosterone (T) or dihydrotestosterone (DHT),
finasteride, but not Permixon or Bazoton, inhibited T stimulated prostate growth, while
None of the three compounds inhibited DHT stimulated growth. These results demonstrate
that finasteride inhibits 5 alpha reductase, while Permixon and Bazoton have neither
anti-androgen nor 5 alpha reductase inhibitory activity. In addition, in a 7 day human
clinical trial, finasteride, but not Permixon or placebo, decreased serum DHT in men,
further confirming the lack of 5 alpha reductase inhibition by Permixon. Finasteride and
the plant extracts listed above do not inhibit the binding of DHT to the rat prostatic
androgen receptor (concentrations to 100 micrograms/ml). Based on these results, it is
unlikely that these plant extracts would shrink the prostate by inhibiting androgen action
or 5 alpha reductase.